Enliven Therapeutics's total assets for Q3 2025 were $490.88M, a decrease of ― from the previous quarter. ELVN total liabilities were $14.75M for the fiscal quarter, a ― a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.